Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr;14(10):907-917.
doi: 10.2217/fon-2017-0531. Epub 2017 Dec 20.

Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions

Catherine E Handy  1 , Emmanuel S Antonarakis  1
Affiliations
Review

Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions

Catherine E Handy et al. Future Oncol. 2018 Apr.

Abstract

Sipuleucel-T, an autologous cellular immunotherapy manufactured from antigen-presenting cells primed to recognize prostatic acid phosphatase, was the first immunotherapy product approved by the US FDA. It was approved for men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer after it was shown to provide a survival advantage. Additional studies have examined its use in other clinical settings and in combination with other approved and investigational immunotherapy agents. This review will discuss the pivotal trials leading to approval, will outline some of the biomarkers associated with its efficacy and will review some of the ongoing combination strategies. Maximizing the efficacy of sipuleucel-T through better patient selection or through combination approaches remains the challenge of the future.

Keywords: biomarkers; cancer vaccine; castration-resistant prostate cancer; immunotherapy; prostate cancer; sipuleucel-T.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

This work was partially supported by NIH grant P30 CA006973 (ES Antonarakis) and Conquer Cancer Foundation/Bristol-Meyers Squibb Young Investigator Award (CE Handy). ES Antonarakis is a paid consultant/advisor to Janssen, Astellas, Sanofi, Dendreon, Medivation, ESSA, AstraZeneca, Clovis and Merck; he has received research funding to his institution from Janssen, Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, Tokai, Bristol Myers-Squibb, AstraZeneca, Clovis and Merck; and he is the co-inventor of a biomarker technology that has been licensed to Tokai and Qiagen. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Figures

<b>Figure 1.</b>
Figure 1.. Mechanism of action of sipuleucel-T.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J. Clin. 2017;67(1):7–30. - PubMed
    1. Surveillance Epidemiology and End Results Program. Cancer statistics. 2017. www.cancer.gov/about-cancer/understanding/statistics
    1. Herget KA, Patel DP, Hanson HA, Sweeney C, Lowrance WT. Recent decline in prostate cancer incidence in the United States, by age, stage, and Gleason score. Cancer Med. 2016;5(1):136–141. - PMC - PubMed
    1. Hamdy FC, Donovan JL, Lane JA, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N. Engl. J. Med. 2016;375(15):1415–1424. - PubMed
    1. Kupelian PA, Mahadevan A, Reddy CA, Reuther AM, Klein EA. Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer. Urology. 2006;68(3):593–598. - PubMed

MeSH terms

LinkOut - more resources